成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Biomolecules >>article
Biomolecules

Biomolecules

IF: 4.79
Download PDF

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study.

Published:14 October 2022 DOI: 10.3390/biom12101482 PMID: 36291690
Runzhen Chen, Hanjun Zhao, Jinying Zhou, Ying Wang, Jiannan Li, Xiaoxiao Zhao, Nan Li, Chen Liu, Peng Zhou, Yi Chen, Li Song, Hongbing Yan

Abstract

Background. In vivo studies show that LL-37 inhibits the progression of atherosclerosis and predicts a lower risk of recurrent ischemia in patients with acute myocardial infarction (AMI), which could be mediated by the modulation of lipid metabolism. The current study aimed to investigate the effects of various lipid contents on the prognostic impacts of LL-37 in patients with AMI. Methods. A total of 1567 consecutive AMI patients were prospectively recruited from March 2017 to January 2020. Patients were firstly stratified into two groups by the median level of LL-37 and then stratified by levels of various lipid contents and proprotein convertase subtilisin/kexin type 9 (PCSK9). Cox regression with multiple adjustments was performed to analyze associations between LL-37, lipid profiles, PCSK9, and various outcomes. The primary outcome was major adverse cardiovascular event (MACE), a composite of all-cause death, recurrent MI, and ischemic stroke. Results. During a median follow-up of 786 (726?1107) days, a total of 252 MACEs occurred. A high level of LL-37 was associated with lower risk of MACE in patients with elevated lipoprotein(a) (≥300 mg/L, hazard ratio (HR): 0.49, 95% confidence interval (CI): 0.29?0.86, p = 0.012) or PCSK9 levels above the median (≥47.4 ng/mL, HR: 0.57, 95% CI: 0.39?0.82, p < 0.001), which was not observed for those without elevated lp(a) (<300 mg/L, HR: 0.96, 95% CI: 0.70?1.31, p = 0.781, pinteraction = 0.035) or PCSK9 (<47.4 ng/mL, HR: 1.02, 95% CI: 0.68?1.54, p = 0.905, pinteraction = 0.032). Conclusions. For patients with AMI, a high level of LL-37 was associated with lower ischemic risk among patients with elevated lp(a) and PCSK9.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
antibacterial protein ll-37 amide (human) 597562-32-8 C205H341N61O52 124 suppliers $294.00-$2696.20
LP(A) 10 suppliers Inquiry
LIPID KIT 8 suppliers Inquiry
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) 1 suppliers Inquiry

Similar articles

IF:0

Safety of ketoprofen in the elderly: a prospective study on 20,000 patients.

Scandinavian journal of rheumatology. Supplement X Le Loet,etc Published: 1 January 1989
IF:8.3

Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.

ACS Applied Materials & Interfaces Chia-Hsuin Chang, Yi-Cheng Chang,etc Published: 1 March 2015
IF:10.5

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

JAMA Network Open Katherine L. Modzelewski, Alexandra Pipilas,etc Published: 2 May 2024